Table 2.
Marginal effects of policy phases
| Marginal effect | SE | Unadjusted p-value | Unadjusted groups | Bonferroni p-value | Bonferroni groups | |
|---|---|---|---|---|---|---|
| Insomnia: “not at all” | ||||||
| Policy phase | ||||||
| Phase 1 | -0.301 | 0.042 | 0.000 | - | - | - |
| Phase 2 | -0.355 | 0.036 | 0.000 | - | - | - |
| Phase 3 | -0.128 | 0.024 | 0.000 | - | - | - |
| Policy phase x Age group | ||||||
| Phase 1 x 16–34 | -0.486 | 0.103 | 0.000 | A | 0.000 | A |
| Phase 1 x 35–54 | -0.318 | 0.053 | 0.000 | AB | 0.000 | AB |
| Phase 1 x 55 or more | -0.173 | 0.063 | 0.006 | B | 0.017 | B |
| Phase 2 x 16–34 | -0.487 | 0.088 | 0.000 | A | 0.000 | A |
| Phase 2 x 35–54 | -0.335 | 0.050 | 0.000 | A | 0.000 | A |
| Phase 2 x 55 or more | -0.291 | 0.051 | 0.000 | A | 0.000 | A |
| Phase 3 x 16–34 | -0.269 | 0.060 | 0.000 | A | 0.000 | A |
| Phase 3 x 35–54 | -0.163 | 0.039 | 0.000 | AB | 0.000 | AB |
| Phase 3 x 55 or more | -0.064 | 0.035 | 0.068 | B | 0.203 | B |
| Insomnia: “somewhat” | ||||||
| Policy phase | ||||||
| Phase 1 | 0.159 | 0.017 | 0.000 | - | - | - |
| Phase 2 | 0.168 | 0.015 | 0.000 | - | - | - |
| Phase 3 | 0.084 | 0.016 | 0.000 | - | - | - |
| Policy phase x Age group | ||||||
| Phase 1 x 16–34 | 0.325 | 0.038 | 0.000 | 0.000 | ||
| Phase 1 x 35–54 | 0.176 | 0.025 | 0.000 | 0.000 | ||
| Phase 1 x 55 or more | 0.084 | 0.024 | 0.000 | 0.001 | ||
| Phase 2 x 16–34 | 0.325 | 0.039 | 0.000 | 0.000 | ||
| Phase 2 x 35–54 | 0.180 | 0.023 | 0.000 | 0.000 | ||
| Phase 2 x 55 or more | 0.100 | 0.023 | 0.000 | 0.000 | ||
| Phase 3 x 16–34 | 0.210 | 0.042 | 0.000 | 0.000 | B | |
| Phase 3 x 35–54 | 0.108 | 0.025 | 0.000 | 0.000 | AB | |
| Phase 3 x 55 or more | 0.036 | 0.020 | 0.064 | 0.191 | A | |
| Insomnia: “very much” | ||||||
| Policy phase | ||||||
| Phase 1 | 0.142 | 0.030 | 0.000 | - | - | - |
| Phase 2 | 0.187 | 0.030 | 0.000 | - | - | - |
| Phase 3 | 0.045 | 0.010 | 0.000 | - | - | - |
| Policy phase x Age group | ||||||
| Phase 1 x 16–34 | 0.161 | 0.072 | 0.025 | A | 0.075 | A |
| Phase 1 x 35–54 | 0.142 | 0.034 | 0.000 | A | 0.000 | A |
| Phase 1 x 55 or more | 0.090 | 0.041 | 0.030 | A | 0.091 | A |
| Phase 2 x 16–34 | 0.162 | 0.056 | 0.004 | A | 0.011 | A |
| Phase 2 x 35–54 | 0.155 | 0.037 | 0.000 | A | 0.000 | A |
| Phase 2 x 55 or more | 0.191 | 0.050 | 0.000 | A | 0.000 | A |
| Phase 3 x 16–34 | 0.059 | 0.020 | 0.002 | A | 0.007 | A |
| Phase 3 x 35–54 | 0.055 | 0.015 | 0.000 | A | 0.001 | A |
| Phase 3 x 55 or more | 0.027 | 0.016 | 0.079 | A | 0.238 | A |
This table reports discrete changes in respondents’ probability of experiencing no, moderate or severe insomnia at different policy phases (compared to the pre-pandemic baseline). Estimates sharing the same letter in the same phase-related group are not significantly different at the 5% level